Clinical Trials


Home Clinical Trials Investigational drug trial for Neuromyelitis Optica


Now enrolling...The use of an investigational drug (SA237) for Neuromyelitis Optica (NMO)

Posted March 17, 2016 by Jeneane Nichol Henry

DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

 

To qualify, patients must:

Þ Age 18 to 74, inclusive at time of informed consent

Þ Pts must be diagnosed with NMO or NMOSD (by definition)

Þ Clinical evidence of at least 1 documented relapse within 12 months

Þ EDSS score from 0 to 6.5 at screening

 

For more information, please contact Jeneane Henry, RN BSN, Clinical Research Nurse at 804-828-7802 or jeneane.henry@vcuhealth.org

 

Investigators:

Warren L. Felton III, MD (Principal Investigator), Dept. of Neurology at VCU

Unsong Oh, MD (Sub-Investigator), Dept. of Neurology at VCU

 

Clinical Research Nurse / Study Coordinator:

Jeneane Henry, RN BSN, Dept. of Neurology at VCU